about
Patient considerations in the management of ulcerative colitis - role of vedolizumabCX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.Use of methotrexate in inflammatory bowel disease in 2014: A User's Guide.Optimizing drug therapy in inflammatory bowel disease.Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease.Video capsule endoscopy in inflammatory bowel disease: past, present, and future redux.Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.Internet Searches About Therapies Do Not Impact Willingness to Accept Prescribed Therapy in Inflammatory Bowel Disease Patients.The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.TNF-alpha antagonist induced lupus on three different agents.Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.Effect of physician education and patient counseling on inpatient nonsurgical percutaneous feeding tube placement rate, indications, and outcome.Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts.Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab.Images in clinical medicine. Fulminant ulcerative colitisInfliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index caseAn unusual case of diarrheaThe power of poop: patients getting ahead of their doctors using self-administered fecal transplants
P50
Q26796432-062F5DDB-82E9-474B-8449-22A479D44920Q33964256-20922292-559B-4331-8EAB-90E13C86E499Q34047653-5188B77D-683A-412C-8EBA-BBA739C13543Q37123773-A5AA0B59-2582-47F1-98B7-834AADAC3C12Q37467519-3EDD8F4D-F0A3-4995-90EB-0E36FBFE5B70Q37692377-4EC556D3-362A-4AAD-A6D5-9730FA39B0B5Q38620906-B2718BDC-BE4D-4D9B-B0A5-DC34BBCF5F8CQ40218496-522C90CE-69E9-445A-B296-93148F72AA4FQ40703329-127343A2-FC82-4C6D-BD97-FD8E3061CE07Q43576777-B1A3BC5F-0EFE-41D6-8231-446BDC568DC4Q47438977-3FDD0AE1-76DA-4D2D-A094-DCC76ADB094AQ47964826-F556F055-45C6-4391-8DA4-7CD59459EE05Q48156263-AA90F70F-986A-4EE3-8029-63B89FED68ADQ50498303-8A7204D3-C7B8-43D3-B4EF-F50A6A7C7170Q51140445-6BD1033D-F7F1-414A-8CA6-43A3B2A36821Q51621662-DE6EE6E2-04A7-47B5-B5DD-5C6E3B378E0BQ53231217-05C7A43D-359A-489B-86CC-F55024FDA010Q82941164-85B8A53E-2A9C-4D44-93B9-607A69B3D7AAQ84152883-6F374408-F903-4872-9C03-981554DFF6A8Q84392264-883D6D06-244E-4E17-8D8C-C904D2421B71Q87812248-0378388B-3E61-434E-9D2A-6912FE28BAC9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Arun Swaminath
@ast
Arun Swaminath
@en
Arun Swaminath
@es
Arun Swaminath
@nl
Arun Swaminath
@sl
type
label
Arun Swaminath
@ast
Arun Swaminath
@en
Arun Swaminath
@es
Arun Swaminath
@nl
Arun Swaminath
@sl
prefLabel
Arun Swaminath
@ast
Arun Swaminath
@en
Arun Swaminath
@es
Arun Swaminath
@nl
Arun Swaminath
@sl
P106
P31
P496
0000-0003-3495-012X